RecruitingPhase 1NCT06484985
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
An Open-label, Multicenter, Phase I Safety Study of AXT-1003 in Subjects With Advanced Malignant Tumors
Sponsor
Axter Therapeutics (Beijing) Co., Ltd
Enrollment
78 participants
Start Date
Sep 4, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This is a Phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in patients with advanced malignancies.
Eligibility
Min Age: 18 Years
Inclusion Criteria11
- For Ia dose escalation part only:
- R/R NHL: Locally histopathological diagnosis of relapsed/refractory non-Hodgkin lymphoma (R/R NHL), who have progressed or been intolerant after the available standard therapies, or have no access to the standard therapies.
- Advanced solid tumors: Locally histopathological diagnosis of locally advanced unresectable and metastatic solid tumors,The above subjects have progressed or been intolerant after the available standard therapies, or have no access to the standard therapies.
- For Ib dose expansion part only: Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL)
- Eastern Cooperative Oncology Group (ECOG) performance status scale 0 to 1.
- Have a life expectancy of at least 3 months.
- For Ib dose expansion part and not mandatory for Ia dose escalation part: Subjects with R/R NHL must have measurable lesions as defined by Lugano 2014 criteria. Subjects with advanced solid tumors must have measurable or evaluable lesions as defined by RECIST 1.1.
- Adequate organ and bone marrow functions.
- The adequate washout period for prior therapy .
- Subjects must use a highly effective contraception method throughout the study and for 3 months after discontinuation of the study drug.
- Signed ICF and willing to comply with all the requirements in the protocol.
Exclusion Criteria12
- Diagnosis of precursor B-cell lymphoblastic leukemia/lymphoma, precursor T-cell lymphoblastic leukemia/lymphoma, precursor NK cell lymphoblastic leukemia/lymphoma. Diagnosis of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL).
- Central nervous system infiltration.
- Uncontrolled or significant cardiovascular disease.
- Major surgery within 4 weeks before the first dose of study drug.
- Known or suspected hypersensitivity to AXT-1003 or any of the excipients.
- Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of AXT-1003.
- History of other malignancies prior to enrollment; except for subjects with basal cell carcinoma of skin, squamous cell carcinoma of skin, cervical carcinoma in situ, or other carcinomas in situ who have undergone possible curative treatment and do not have disease recurrence within 5 years since starting the treatment.
- Any prior treatment-related clinically significant toxicities that have not resolved to Grade ≤ 1 or prior treatment-related toxicities that are clinically unstable and clinically significant at time of enrollment.
- Active infection requiring systemic treatment.
- Infection with hepatitis B virus with positive hepatitis B surface antigen, or hepatitis C virus with detectable anti-hepatitis C circulating viral RNA.
- Subjects known to be infected with human immunodeficiency virus and active tuberculosis.
- Females who are pregnant or breastfeeding.
Interventions
DRUGAXT-1003
AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06484985
Related Trials
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT0516951526 locations
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT0722226712 locations
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT0509813227 locations
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
NCT05006716120 locations
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT0563564316 locations